Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DRTS
stocks logo

DRTS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.123
-5.14%
--
--
-0.120
-0%
--
--
-0.120
-7.69%
Estimates Revision
The market is revising No Change the revenue expectations for Alpha Tau Medical Ltd. (DRTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 12.78%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+12.78%
In Past 3 Month
Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.060
sliders
Low
5.00
Averages
7.00
High
9.00
Current: 4.060
sliders
Low
5.00
Averages
7.00
High
9.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2025-03-17
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2025-03-17
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alpha Tau Medical Ltd (DRTS.O) is -8.40, compared to its 5-year average forward P/E of -13.08. For a more detailed relative valuation and DCF analysis to assess Alpha Tau Medical Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.08
Current PE
-8.40
Overvalued PE
-1.38
Undervalued PE
-24.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.02
Undervalued EV/EBITDA
-9.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
400.93
Current PS
0.00
Overvalued PS
1130.02
Undervalued PS
-328.16
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DRTS News & Events

Events Timeline

(ET)
2025-12-02
09:11:00
Alpha Tau Receives FDA Approval for Prostate Cancer Study Using Alpha DaRT Technology
select
2025-11-20 (ET)
2025-11-20
16:08:20
Alpha Tau Announces Q3 Earnings Per Share of 32 Cents, Exceeding Consensus Estimate of 12 Cents
select
2025-10-21 (ET)
2025-10-21
08:31:39
Alpha Tau obtains license for radioactive materials in New Hampshire
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
PinnedAlpha Tau Medical Receives FDA Approval for Prostate Cancer Clinical Trial
  • Clinical Trial Launch: Alpha Tau Medical has received FDA approval to initiate a clinical trial for its Alpha DaRT® technology targeting locally recurrent prostate cancer, with plans to enroll up to 12 patients to evaluate the safety and efficacy of the treatment, thereby providing new options for patients.
  • Market Demand Response: With over 300,000 new prostate cancer cases expected in the U.S. in 2025, according to the National Cancer Institute, Alpha Tau's new therapy aims to offer alternatives for patients facing recurrence, addressing clinical needs and enhancing market competitiveness.
  • Technological Innovation: Alpha DaRT® utilizes intratumoral delivery of radium-224 to precisely destroy tumors while sparing surrounding healthy tissue, showcasing its potential to transform existing treatment paradigms in oncology.
  • Company Growth Prospects: This approval marks Alpha Tau's fifth IDE in the U.S., indicating the company's expansion across various tumor types and further solidifying its market position in cancer treatment, which is expected to drive future business growth.
[object Object]
Preview
1.0
12-01Globenewswire
Alpha Tau Medical to Present at Two Investor Conferences in December 2025
  • Investor Conference Schedule: Alpha Tau Medical's CFO Raphi Levy will present a 25-minute fireside chat at the Piper Sandler Healthcare Conference on December 3, 2025, aimed at enhancing the company's visibility among investors and attracting potential funding.
  • Virtual Conference Participation: Additionally, Levy will present at Sidoti's Year-End Virtual Investor Conference on December 10, 2025, further expanding engagement opportunities with investors and increasing market awareness of the Alpha DaRT technology.
  • One-on-One Investor Meetings: At both conferences, Levy will be available for one-on-one investor meetings, designed to discuss the company's strategic development and the commercial potential of Alpha DaRT, thereby generating greater investor interest.
  • Technology Background Introduction: Alpha DaRT is an innovative cancer therapy technology focused on delivering radium-224 via intratumoral injection to precisely target solid tumors, aiming to enhance treatment efficacy while minimizing damage to surrounding healthy tissue, showcasing the company's technological edge in oncology treatment.
[object Object]
Preview
1.0
12-01Newsfilter
Alpha Tau Medical CFO to Present at Two Investor Conferences in December 2025
  • Investor Conference Schedule: Alpha Tau Medical CFO Raphi Levy will present a 25-minute fireside chat at the Piper Sandler Healthcare Conference in New York on December 3, 2025, aimed at increasing investor awareness of the company's innovative cancer treatment technology.
  • Virtual Conference Participation: Additionally, Levy will present at Sidoti's Year End Virtual Investor Conference on December 10, 2025, further expanding opportunities for interaction with potential investors.
  • One-on-One Meeting Opportunities: At both conferences, Levy will be available for one-on-one investor meetings, encouraging investors to schedule discussions through Piper Sandler and Sidoti representatives to gain deeper insights into the company's strategic developments.
  • Technology Background Introduction: Alpha Tau focuses on developing the Alpha DaRT® technology, which targets solid tumors through localized radiation therapy, showcasing the company's innovative potential in cancer treatment and possibly attracting more investor interest.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alpha Tau Medical Ltd (DRTS) stock price today?

The current price of DRTS is 4.06 USD — it has increased 4.64 % in the last trading day.

arrow icon

What is Alpha Tau Medical Ltd (DRTS)'s business?

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

arrow icon

What is the price predicton of DRTS Stock?

Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alpha Tau Medical Ltd (DRTS)'s revenue for the last quarter?

Alpha Tau Medical Ltd revenue for the last quarter amounts to -10.73M USD, increased 29.43 % YoY.

arrow icon

What is Alpha Tau Medical Ltd (DRTS)'s earnings per share (EPS) for the last quarter?

Alpha Tau Medical Ltd. EPS for the last quarter amounts to -9120000.00 USD, increased 221.47 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alpha Tau Medical Ltd (DRTS)'s fundamentals?

The market is revising No Change the revenue expectations for Alpha Tau Medical Ltd. (DRTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 12.78%.
arrow icon

How many employees does Alpha Tau Medical Ltd (DRTS). have?

Alpha Tau Medical Ltd (DRTS) has 125 emplpoyees as of December 05 2025.

arrow icon

What is Alpha Tau Medical Ltd (DRTS) market cap?

Today DRTS has the market capitalization of 339.35M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free